European Archives - Page 548 of 1125 - European Medical Journal

EMJ Oncology 9 [Supplement 6] 2021

During a symposium at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021, Eric Van Cutsem, Angela Lamarca, Nicola Normanno, and Arndt Vogel discussed better patient identification, biomarkers, genomic testing, and emerging therapies in the context of cholangiocarcinoma (CCA). The challenges associated with precision medicine were also explored.

Nutritional Approaches for Weight Management, and Prevention and Remission of Type 2 Diabetes

Visceral or intra-organ fat (VIF) accumulation may be a better indication of cardiovascular and metabolic disease risk than BMI…

Dubious Diets

This week, Jonathan tucks into the contentious topic of diets. On his plate is the impact of overconsumption, how diet can interact with the microbiome, and his views on intolerances and milk alternatives.

EMJ Dermatology 9 [Supplement 5] 2021

During a Janssen-sponsored, live satellite symposium at the 6th World Psoriasis and Psoriatic Arthritis Conference (WPPAC) 2021, Kilian Eyerich and Rik Lories examined the crucial role of the IL-23 pathway in the management of psoriasis and psoriatic arthritis (PsA).

Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future

Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future

Novartis sponsored ESMO 2021 Satellite Symposium: Navigating the Current Treatment Landscape Faculty: Prof Eric…

Where Do We Begin? The Key Role of the IL-23 Pathway in Psoriasis and Psoriatic Arthritis

This Janssen-sponsored live satellite symposium, entitled ‘Where do we begin? The key role of the IL-23 pathway in psoriasis and psoriatic…

Clare Hague on drug pricing and market access

Clare Hague, Senior Director, Haematology Market Access, Europe, the Middle East, and Africa, Janssen, discusses drug pricing.

EMJ Rheumatology 8 [Supplement 4] 2021 Feature Image

Improving Knowledge in ANCA-Associated Vasculitis: What Do Patients and Doctors Think? Interviews with Two Opinion Leaders and Two Patient Representatives

AAV is a rare and severe multisystem disease affecting the small arteries.1,2 The condition is characterised by systemic inflammation across multiple body sites including the lungs, joints, kidneys, nerves, ears, and nose.1,2 Glucocorticoids and immunosuppressants form the cornerstone of current treatment approaches.

EMJ Rheumatology 8 [Supplement 4] 2021 Feature Image

EMJ Rheumatology 8 [Supplement 4] 2021

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) refers to a group of rare autoimmune inflammatory…

COVID-19 Infection in a Patient with AML

The COVID-19 outbreak, first identified in the Wuhan district of China in December 2019, was declared a pandemic by the World Health…